Your browser doesn't support javascript.
loading
PRRX1 silencing is required for metastatic outgrowth in melanoma and is an independent prognostic of reduced survival in patients.
Ferreres, Josep R; Vinyals, Antònia; Campos-Martin, Rafael; Espín, Roderic; Podlipnik, Sebastian; Ramos, Raquel; Bertran, Esther; Carrera, Cristina; Marcoval, Joaquim; Malvehy, Josep; Fabregat, Isabel; Puig, Susana; Fabra, Àngels.
Afiliação
  • Ferreres JR; TGF-ß and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospital Duran i Reynals, Barcelona, Spain.
  • Vinyals A; Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), ISCIII, Instituto de Salud Carlos III, Madrid, Spain.
  • Campos-Martin R; Dermatology Service, IDIBELL, Hospital Universitari de Bellvitge, Barcelona, Spain.
  • Espín R; TGF-ß and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospital Duran i Reynals, Barcelona, Spain.
  • Podlipnik S; Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), ISCIII, Instituto de Salud Carlos III, Madrid, Spain.
  • Ramos R; Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, University of Cologne, Germany.
  • Bertran E; Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program (IDIBELL), Barcelona, Spain.
  • Carrera C; Dermatology Department, Melanoma Unit, Hospital Clínic, IDIBAPS & University of Barcelona, Spain.
  • Marcoval J; Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), ISCIII, Instituto de Salud Carlos III, Madrid, Spain.
  • Malvehy J; TGF-ß and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospital Duran i Reynals, Barcelona, Spain.
  • Fabregat I; Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), ISCIII, Instituto de Salud Carlos III, Madrid, Spain.
  • Puig S; TGF-ß and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospital Duran i Reynals, Barcelona, Spain.
  • Fabra À; Centro de Investigaciones Biomédicas en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), ISCIII, Instituto de Salud Carlos III, Madrid, Spain.
Mol Oncol ; 2024 Jul 08.
Article em En | MEDLINE | ID: mdl-38978350
ABSTRACT
Paired related homeobox 1 (PRRX1) is an inducer of epithelial-to-mesenchymal transition (EMT) in different types of cancer cells. We detected low PRRX1 expression in nevus but increased levels in primary human melanoma and cell lines carrying the BRAFV600E mutation. High expression of PRRX1 correlates with invasiveness and enrichment of genes belonging to the EMT programme. Conversely, we found that loss of PRRX1 in metastatic samples is an independent prognostic predictor of poor survival for melanoma patients. Here, we show that stable depletion of PRRX1 improves the growth of melanoma xenografts and increases the number of distant spontaneous metastases, compared to controls. We provide evidence that loss of PRRX1 counteracts the EMT phenotype, impairing the expression of other EMT-related transcription factors, causing dysregulation of the ERK and signal transducer and activator of transcription 3 (STAT3) signaling pathways, and abrogating the invasive and migratory properties of melanoma cells while triggering the up-regulation of proliferative/melanocytic genes and the expression of the neural-crest-like markers nerve growth factor receptor (NGFR; also known as neurotrophin receptor p75NTR) and neural cell adhesion molecule L1 (L1CAM). Overall, our results indicate that loss of PRRX1 triggers a switch in the invasive programme, and cells de-differentiate towards a neural crest stem cell (NCSC)-like phenotype that accounts for the metastatic aggressiveness.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article